Galapagos NV (Galapagos NV) FCF Margin % : -206.14% (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Galapagos NV's Free Cash Flow for the three months ended in Mar. 2024 was $-139.9 Mil. Galapagos NV's Revenue for the three months ended in Mar. 2024 was $67.9 Mil. Therefore, Galapagos NV's FCF Margin % for the quarter that ended in Mar. 2024 was -206.14%.

As of today, Galapagos NV's current FCF Yield % is -25.34%.

The historical rank and industry rank for Galapagos NV's FCF Margin % or its related term are showing as below:

GLPGF' s FCF Margin % Range Over the Past 10 Years
Min: -306.49 Med: -117.25 Max: 378.84
Current: -188.62

During the past 13 years, the highest FCF Margin % of Galapagos NV was 378.84%. The lowest was -306.49%. And the median was -117.25%.

GLPGF's FCF Margin % is ranked worse than
53.66% of 1038 companies
in the Biotechnology industry
Industry Median: -144.05 vs GLPGF: -188.62

Galapagos NV FCF Margin % Historical Data

The historical data trend for Galapagos NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV FCF Margin % Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

378.84

-108.49

-239.65

-222.80

-177.39

Galapagos NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-169.28	-47.82	-101.66	35.79	-206.14

Competitive Comparison of Galapagos NV's FCF Margin %

For the Biotechnology subindustry, Galapagos NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Galapagos NV's FCF Margin % falls into.

Galapagos NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Galapagos NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-463.732	/	261.422
	=	-177.39 %

Galapagos NV's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-139.887	/	67.861
	=	-206.14 %

Galapagos NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of Galapagos NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

GLPG:USA GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.